HLB group stocks all hit the daily upper limit in the regular session on the 28th, the first trading day after the Chuseok holiday. The news of the U.S. Food and Drug Administration (FDA) approving a new drug has stimulated investor sentiment, and market attention is now focused on whether the rally will continue through the last two trading days of September, the 29th and 30th.

■ Closing Prices by Stock

As of the close of the regular session on the 28th, HLB (028300) finished at 39,700 won, up 29.95% from the previous trading day. HLB Pharmaceutical (047920) closed at 9,620 won, up 30.00%, and HLB Innovation (024850) finished trading at 19,680 won, up 29.98%.

The other affiliates also surged together. HLB Life Science closed at 3,405 won, up 29.96%, and HLB Biostep ended at 3,250 won, up 30.00%. HLB Therapeutics rose 29.84% to 2,580 won, and HLB Panagine climbed 29.94% to 1,432 won. HLB Global closed up 29.81% at 2,055 won, HLB Genex ended up 29.82% at 2,320 won, and HLB Pep finished trading at 5,590 won, up 30.00%.

■ FDA Approval of Bile Duct Cancer Targeted Therapy 'Riviktua'

The simultaneous surge of HLB group stocks on the day is interpreted as being driven by the news of the U.S. FDA approval of the bile duct cancer treatment. On the 24th, HLB announced that its U.S. subsidiary Elevar Therapeutics received FDA approval for the bile duct cancer targeted therapy 'Riviktua' (ingredient name: futibatinib, Korean transliteration: lirapugratinib). Riviktua was approved as a second-line treatment for adult patients with locally advanced or metastatic bile duct cancer with confirmed FGFR2 gene fusion or rearrangement.

■ Volatility in Focus for the September 29–30 Sessions

Ahead of the last two trading days of September, the key points of interest are whether expectations from the FDA approval will lead to further gains, or whether profit-taking sell orders will emerge following the sharp short-term rally.

In particular, given that many group stocks rose to their daily price limit in a single day, the possibility of increased volatility going forward must be kept in mind. Apart from the positive news of the new drug approval, it is necessary to continuously monitor the actual commercialization process and whether future earnings will reflect it.

[※ This article is for investment reference purposes only and does not recommend the purchase or sale of gold. Investment decisions and the responsibility for them rest with the investor.]